GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (MEX:SAVA) » Definitions » Shiller PE Ratio

Cassava Sciences (MEX:SAVA) Shiller PE Ratio : (As of Sep. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cassava Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cassava Sciences Shiller PE Ratio Historical Data

The historical data trend for Cassava Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Shiller PE Ratio Chart

Cassava Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cassava Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cassava Sciences's Shiller PE Ratio

For the Biotechnology subindustry, Cassava Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cassava Sciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cassava Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's Shiller PE Ratio falls into.



Cassava Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cassava Sciences's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, Cassava Sciences's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=2.382/132.5538*132.5538
=2.382

Current CPI (Jun. 2024) = 132.5538.

Cassava Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201409 -7.519 100.428 -9.924
201412 -5.162 99.070 -6.907
201503 -6.403 99.621 -8.520
201506 -7.688 100.684 -10.122
201509 -9.463 100.392 -12.495
201512 -12.037 99.792 -15.989
201603 -15.665 100.470 -20.667
201606 -8.507 101.688 -11.089
201609 -10.441 101.861 -13.587
201612 -8.659 101.863 -11.268
201703 -7.908 102.862 -10.191
201706 -11.569 103.349 -14.838
201709 -7.259 104.136 -9.240
201712 -7.267 104.011 -9.261
201803 -5.995 105.290 -7.547
201806 -7.074 106.317 -8.820
201809 -2.058 106.507 -2.561
201812 -0.785 105.998 -0.982
201903 -1.552 107.251 -1.918
201906 -1.153 108.070 -1.414
201909 -0.790 108.329 -0.967
201912 -1.509 108.420 -1.845
202003 -1.172 108.902 -1.427
202006 -1.154 108.767 -1.406
202009 -1.325 109.815 -1.599
202012 -1.790 109.897 -2.159
202103 -1.840 111.754 -2.182
202106 -2.588 114.631 -2.993
202109 -4.935 115.734 -5.652
202112 -7.180 117.630 -8.091
202203 -8.761 121.301 -9.574
202206 -9.657 125.017 -10.239
202209 -10.259 125.227 -10.859
202212 -9.163 125.222 -9.700
202303 -10.454 127.348 -10.881
202306 -10.801 128.729 -11.122
202309 -10.626 129.860 -10.846
202312 -8.487 129.419 -8.693
202403 -7.136 131.776 -7.178
202406 2.382 132.554 2.382

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cassava Sciences  (MEX:SAVA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cassava Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cassava Sciences Business Description

Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.